DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.18) per share for the quarter.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
DiaMedica Therapeutics Trading Down 3.3 %
DiaMedica Therapeutics stock opened at $3.87 on Wednesday. The stock has a 50 day moving average of $4.46 and a 200-day moving average of $5.02. The stock has a market cap of $165.85 million, a P/E ratio of -6.91 and a beta of 1.29. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82.
Wall Street Analyst Weigh In
Separately, HC Wainwright raised their price objective on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, March 19th.
Get Our Latest Stock Analysis on DMAC
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
